CROI 2019 - CROI 2019

WORKSHOP: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

"UPDATE ON HIV VIROLOGY" by Paul Bieniasz of The Rockefeller University, New York, NY, USA

WORKSHOP: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

"UPDATE ON HIV IMMUNOLOGY" by Penelope L. Moore of University of Witwatersrand, Johannesburg, South Africa

WORKSHOP: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

"UPDATE ON HIV PREVENTION" by Sharon L. Hillier of University of Pittsburgh, Pittsburgh, PA, USA

WORKSHOP: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

"UPDATE ON TUBERCULOSIS TREATMENT AND PREVENTION" by Constance A. Benson of University of California San Diego, San Diego, CA, USA

WORKSHOP: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

"UPDATE ON HIV CURE" by Katharine J Bar of University of Pennsylvania, Philadelphia, PA, USA

WORKSHOP: MARTIN DELANEY PRESENTATION

"DISCOVERING THE ART IN SCIENCE (AND MEDICINE): THE HUMAN CONNECTION" by Dawn Averitt of The Well Project, Women’s Research Initiative on HIV/AIDS, South Strafford, VT, USA

WORKSHOP: FRONTIERS IN LABORATORY SCIENCE

"ENGINEERING THE LATENT RESERVOIR" by Paula Cannon of University of Southern California, Los Angeles, CA, USA

WORKSHOP: FRONTIERS IN LABORATORY SCIENCE

"MORE COLORFUL IMMUNOLOGY: TARGETED ISOLATION OF MONOCLONAL ANTIBODIES" by Rosemarie Diana Mason of NIAID, NIH, Bethesda, MD, USA

WORKSHOP: FRONTIERS IN LABORATORY SCIENCE

"NOVEL IMAGING APPROACHES TO CHARACTERIZE AND QUANTIFY VIRAL RESERVOIRS" by Jacob D Estes of Oregon Health and Sciences University, Beaverton, OR, USA

WORKSHOP: CLINICAL TRIAL DESIGN AND ANALYSIS

"FELLOW TRAVELERS: INTERPRETING THE IMPACT OF THE MICROBIOME IN CLINICAL INTERVENTION" by Adam Burgener of Public Health Agency of Canada, Winnipeg, Canada

WORKSHOP: CLINICAL TRIAL DESIGN AND ANALYSIS

"MISSING U: HANDLING AND AVOIDING MISSING DATA IN CLINICAL TRIALS" by Heather Ribaudo of Harvard School of Public Health, Boston, MA, USA

WORKSHOP: CLINICAL TRIAL DESIGN AND ANALYSIS

"DESIGNING & INTERPRETING HIV PREVENTION TRIALS IN THE ERA OF EFFECTIVE INTERVENTIONS" by David Dunn of University College London, London, United Kingdom

WORKSHOP: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS

"HEPATITIS E: CLINICAL CHALLENGES" by Sven Pischke of University Hospital Hamburg–Eppendorf, Hamburg, Germany

WORKSHOP: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS

"HEPATITIS D: CLINICAL CHALLENGES" by Jeffrey S. Glenn of Stanford University, Stanford, CA, USA

WORKSHOP: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS

"NASH IN HIV" by Giada Sebastiani of Chronic Viral Illness Service and Research Institute of McGill University Health Centre, Montreal, Canada

WORKSHOP: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS

"RETREATMENT OF HCV IN ADVANCED LIVER DISEASE" by John D Scott of University of Washington, Seattle, WA, USA

OPENING SESSION

"SESSION HOST" by Richard A. Koup of VRC, NIAID, NIH, Bethesda, MD, USA

OPENING SESSION

"ENDING THE HIV EPIDEMIC: A PLAN FOR THE UNITED STATES" by Anthony S Fauci of NIH, Bethesda, MD, USA

OPENING SESSION

"BERNARD FIELDS LECTURE: DISCOVERY AND DEVELOPMENT OF HIV BROADLY NEUTRALIZING ANTIBODIES" by Michel Nussenzweig of Rockefeller University, New York, NY, USA

OPENING SESSION

"N'GALY-MANN LECTURE: THAILAND'S ACHIEVEMENTS IN HIV TREATMENT, PREVENTION, AND CURE RESEARCH" by Praphan Phanuphak of Thai Red Cross AIDS Research Centre, Bangkok, Thailand

TUESDAY PLENARY SESSION

"DENIAL, DOOM, OR DESTINY? RESURGENT STIS IN HIV CARE AND PREVENTION" by Jeanne M Marrazzo of University of Alabama, Birmingham, USA

TUESDAY PLENARY SESSION

"INFLAMMATION: TAMING THE FLAMES" by Irini Sereti of National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"HPV VACCINE WITH LEEP DID NOT PREVENT RECURRENT CERVICAL HSIL IN HIV-INFECTED WOMEN" by Cindy Firnhaber of University of Colorado Medical Center, Aurora, CO, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"OPTIMAL LUNG CANCER SCREENING CRITERIA AMONG PERSONS LIVING WITH HIV" by Subhashini A Sellers of University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"HIV IS ASSOCIATED WITH DECREASED BREAST CANCER SURVIVAL: A PROSPECTIVE COHORT STUDY" by Katrin Sara Sadigh of Brigham and Women's Hospital, Boston, MA, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"LONG-TERM OUTCOMES OF 58 PATIENTS WITH HIV AND KSHV+ MULTICENTRIC CASTLEMAN DISEASE" by Ramya Ramaswami of HIV AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"REDUCTION OF KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS LATENCY USING CRISPR-CAS9" by For Yue Tso of University of Nebraska - Lincoln, Lincoln, NE, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"QUANTIFICATION OF KSHV DNA AS A DIAGNOSTIC TEST FOR KAPOSI SARCOMA IN AFRICA" by Aggrey Semeere of Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"TWO NOVEL POTENTIAL THERAPEUTIC TARGETS IN THE KSHV LIFE CYCLE" by Thomas Schulz of Medizinischen Hochschule Hannover, Hannover, Germany

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"TARGETING THE NONCANONICAL NF-ΚB PATHWAY REVERSES SIV LATENCY" by Maud Mavigner of Emory University School of Medicine, Atlanta, GA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"NONSUPPRESSIBLE VIREMIA ON ART FROM LARGE CELL CLONES CARRYING INTACT PROVIRUSES" by Elias K Halvas of University of Pittsburgh, Pittsburgh, PA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"EX VIVO AND IN VIVO EDITING OF THE SIV GENOME IN NONHUMAN PRIMATES BY CRISPR-CAS9" by Tricia H. Burdo of Temple University School of Medicine, Philadelphia, PA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"DELAYED VIRAL REBOUND DURING ATI AFTER INFUSION OF CCR5 ZFN-TREATED CD4 T CELLS" by Pablo Tebas of University of Pennsylvania, Philadelphia, PA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"MULTIDOSE IV ROMIDEPSIN: NO INCREASED HIV-1 EXPRESSION IN PERSONS ON ART, ACTG A5315" by Deborah McMahon of University of Pittsburgh, Pittsburgh, PA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"PEMBROLIZUMAB INDUCES HIV LATENCY REVERSAL IN HIV+ INDIVIDUALS ON ART WITH CANCER" by Thomas S Uldrick of Fred Hutchinson Cancer Research Center, Seattle, WA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"POTENT ANTIVIRAL ACTIVITY OF TRISPECIFIC BROADLY NEUTRALIZING HIV ANTIBODIES" by Amarendra Pegu of Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"SUSTAINED HIV-1 REMISSION FOLLOWING HOMOZYGOUS CCR5 DELTA32 ALLOGENIC HSCT" by Ravindra K Gupta of University College London, London, United Kingdom

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"BREAKING BONES IS BAD: INCIDENT FRACTURE AND MORTALITY IN THE HIV OUTPATIENT STUDY" by Linda Ann Battalora of Colorado School of Mines, Golden, CO, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"COPD AND THE RISK FOR MYOCARDIAL INFARCTION BY TYPE IN PEOPLE LIVING WITH HIV" by Kristina Crothers of University of Washington, Seattle, WA, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"SUDDEN CARDIAC DEATH AMONG HIV-INFECTED AND -UNINFECTED VETERANS" by Matthew Freiberg of Vanderbilt University School of Medicine, Nashville, TN, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"HIV POST SCD STUDY: 80% HIGHER RATE OF AUTOPSY-DEFINED SUDDEN ARRHYTHMIC DEATH IN HIV" by Zian H. Tseng of UCSF, San Francisco, CA, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HIV-NEGATIVE INDIVIDUALS: HPTN 077" by Raphael J. Landovitz of University of California Los Angeles, Los Angeles, CA, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"ASSESSING THE PROBIOTIC EFFECT IN TREATED HIV: RESULTS OF ACTG A5350" by Edgar Turner Overton of University of Alabama, Birmingham, AL, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"FACTOR X INHIBITION REDUCES COAGULATION BUT NOT INFLAMMATION IN PERSONS WITH HIV" by Jason V Baker of Hennepin Healthcare Research Institute (U of MN), Minneapolis, MN, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"SAFETY, TOLERABILITY AND IMMUNOLOGIC ACTIVITY OF RUXOLITINIB ADDED TO SUPPRESSIVE ART" by Vincent C. Marconi of School of Medicine, Emory University, Atlanta, GA, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"RANDOMIZED TRIAL OF RALTEGRAVIR-ART VS EFAVIRENZ-ART WHEN INITIATED DURING PREGNANCY" by Mark Mirochnick of Boston University School of Medicine, Hingham, MA, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"RCT OF DOLUTEGRAVIR VS EFAVIRENZ-BASED THERAPY INITIATED IN LATE PREGNANCY: DOLPHIN-2" by Saye Khoo of University of Liverpool Institute of Translational Medicine, Liverpool, United Kingdom

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"MATERNAL HBV VIREMIA IS ASSOCIATED WITH ADVERSE INFANT OUTCOMES IN HIV/HBV WOMEN" by Debika Bhattacharya of University of California Los Angeles, Los Angeles, CA, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"IMPACT OF IMPROVED NUTRITION/SANITATION ON NEURODEVELOPMENT OF HIV-EXPOSED CHILDREN" by Robert Ntozini of Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"UNIQUE IMMUNOLOGICAL AND VIROLOGICAL FEATURES OF EARLY TREATED HIV-INFECTED NEWBORNS" by Pilar Garcia Broncano of Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"NEONATAL ART < 7 DAYS VS 7-28 DAYS REDUCED TIME TO SUPPRESSION" by Sara Dominguez Rodriguez of Fundación Investigación Biomédica Hospital 12 Octubre, Madrid, Spain

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"SAFETY AND PHARMACOKINETICS OF MONOCLONAL ANTIBODY, VRC01LS, IN HIV-EXPOSED NEWBORNS" by Elizabeth J McFarland of University of Colorado School of Medicine, Aurora, CO, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"BICTEGRAVIR/FTC/TAF SINGLE-TABLET REGIMEN IN ADOLESCENTS & CHILDREN: WEEK 48 RESULTS" by Aditya Gaur of St. Jude Children’s Research Hospital, Memphis, TN, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"INCIDENT SYPHILIS RATES AND PREDICTORS IN US WOMEN WITH HIV, 2005-2016" by Jodie Dionne-Odom of University of Alabama at Birmingham, Birmingham, AL, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"PREPARING FOR PREP IN ENGLAND: PREVALENCE AND INCIDENCE OF HIV AND BACTERIAL STIS" by Dana Ogaz of Public Health England, London, United Kingdom

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"EXPANDING TESTING STRATEGIES IN PARIS: A FREE POSTAL COMPREHENSIVE STI TEST KIT" by Heloise M Delagreverie of Hôpital Saint Louis - APHP, Paris, France

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"RANDOMIZED CONTROLLED TRIAL OF INTRAUTERINE DEVICE SAFETY IN WOMEN LIVING WITH HIV" by Catherine S Todd of FHI360, Durham, NC, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"DOUBLE-DOSE LEVONORGESTREL IMPLANT DOES NOT FULLY OVERCOME INTERACTION WITH EFAVIRENZ" by Kimberly K. Scarsi of University of Nebraska, Omaha, NE, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"PHARMACOGENETICS WORSENS AN ADVERSE ANTIRETROVIRAL-HORMONAL CONTRACEPTIVE INTERACTION" by David Haas of Vanderbilt University School of Medicine, Nashville, TN, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"POINT-OF-CARE VIRAL LOAD TESTING IMPROVES HIV VIRAL SUPPRESSION AND RETENTION IN CARE" by Paul K Drain of University of Washington, Seattle, WA, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"EFFECT OF THE HITS INTERVENTION ON HIV TESTING UPTAKE AMONG MEN IN SOUTH AFRICA" by Hae-Young Kim of Africa Health Research Institute, Durban, South Africa

THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS

"THEMED DISCUSSION LEADER" by Blossom Damania of University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS

"PRIMARY ROLE OF KSHV IN PATHOGENESIS OF ENDEMIC AND EPIDEMIC KAPOSI SARCOMA" by Salum Juma Lidenge of University of Nebraska-Lincoln, Lincoln, NE, USA

THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS

"METABOLIC ABNORMALITIES IN CD8 T CELLS FROM HIV+ INDIVIDUALS WITH KAPOSI SARCOMA" by Genevieve Tyndale Clutton of University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS

"SINGLE CELL EVALUATION OF KAPOSI SARCOMA TUMORS REVEALS COMPLEX IMMUNE INFILTRATE" by Warren Phipps of Fred Hutchinson Cancer Research Center, Seattle, WA, USA

THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS

"NEW VARIANT OF KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS IN MEN WHO HAVE SEX WITH MEN" by Aude Jary of AP–HP, Hôpitaux Universitaires Pitié Salpêtrière, Paris, France

THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART

"THEMED DISCUSSION LEADER" by Sarah Palmer of The Westmead Institute for Medical Research, Westmead, NSW, Australia

THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART

"A METHOD TO DETERMINE BOTH THE INTEGRATION SITES AND SEQUENCES OF HIV-1 PROVIRUSES" by Sean Patro of National Cancer Institute, Frederick, MD, USA

THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART

"DISTINCT CHROMOSOMAL POSITIONS OF INTACT HIV-1 PROVIRUSES" by Kevin Einkauf of Brigham and Women's Hospital, Cambridge, MA, USA

THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART

"RELATIONSHIP BETWEEN INTACT HIV-1 PROVIRUSES AND PLASMA REBOUND VIRUSES" by Ching-Lan Lu of The Rockefeller University, New York, NY, USA

THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART

"LANDSCAPE OF HIV-1 INTEGRATION SITES IN LYMPHOID TISSUE FROM ART-TREATED INDIVIDUALS" by Vincent H. Wu of University of Pennsylvania, Philadelphia, PA, USA

THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART

"GENETIC AND AGE DISTRIBUTION OF LATENT HIV SEQUENCES IN CD4+ T-CELL SUBSETS" by Zabrina Brumme of Simon Fraser University, Burnaby, British Columbia, Canada

THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE

"THEMED DISCUSSION LEADER" by Rodolphe Garraffo of Université de Nice-Sophia-Antipolis, Hôpital Pasteur, CHU de Nice, Nice, France

THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE

"PI DRUG-LEVEL TESTING AS A SCREENING TOOL FOR DRUG RESISTANCE IN 2ND-LINE ART FAILURE" by Lucas Etienne Hermans of University Medical Center Utrecht, Johannesburg, South Africa

THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE

"PLASMA EFV AND TFV VS DRIED BLOOD SPOT TFV-DP TO PREDICT VIRAL SUPPRESSION IN WOMEN" by Tamsin Kate Phillips of University of Cape Town, Cape Town, South Africa

THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE

"TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS FOLLOWING ESCALATING TAF/FTC DOSING" by Jenna Yager of University of Colorado, Aurora, CO, USA

THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE

"VALIDATION OF A URINE TFV IMMUNOASSAY FOR REAL-TIME PREP AND ART ADHERENCE TESTING" by Monica Gandhi of University of California San Francisco, San Francisco, CA, USA

THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE

"URINE FTC AND TFV CONCENTRATIONS AS POTENTIAL BIOMARKERS FOR ARV ADHERENCE" by Richard Haaland of Centers for Disease Control and Prevention, Laboratory Branch, Division of HIV/AIDS Prevention, Atlanta, GA, USA

THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?

"THEMED DISCUSSION LEADER" by Judith Aberg of Icahn School of Medicine at Mount Sinai, New York, NY, USA

THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?

"IMPORTANT SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ART" by Catherine Godfrey of National Institute of Health, Bethesda, MD, USA

THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?

"DEPRESSION IS A STRONGER PREDICTOR OF EXECUTIVE DYSFUNCTION IN HIV+ WOMEN THAN MEN" by Leah H Rubin of Johns Hopkins University, Baltimore, MD, USA

THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?

"GENDER AND COINFECTIONS CONTRIBUTE TO IMMUNE ACTIVATION IN TREATED HIV INFECTION" by Hendrik Streeck of Institute for HIV Research, Essen, Germany

THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?

"TENOFOVIR ALAFENAMIDE VS TENOFOVIR DF IN WOMEN: POOLED ANALYSIS OF 7 CLINICAL TRIALS" by Melanie Thompson of AIDS Research Consortium of Atlanta, Atlanta, GA, USA

THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?

"EFFECT OF ANTIRETROVIRAL THERAPY AND IMMUNE RECONSTITUTION ON VAGINAL MICROBIOME" by Zoe Packman of Johns Hopkins University, Baltimore, MD, USA

THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV

"THEMED DISCUSSION LEADER" by Khalil G Ghanem of Johns Hopkins University, Baltimore, MD, USA

THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV

"EFFECTIVE TREATMENT OF LYMPHOGRANULOMA PROCTITIS WITH EXTENDED AZITHROMYCIN REGIMEN" by José L Blanco of Hospital Clinic, Barcelona, Spain

THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV

"ADHERENCE OF HEALTH CARE PROVIDERS TO CDC LUMBAR-PUNCTURE CRITERIA AMONG SYPHILIS/HIV" by Barbara Labella Henriques of Universidad de São Paulo, São Paulo, Brazil

THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV

"HEARING LOSS IN UNSELECTED INDIVIDUALS WITH SYPHILIS" by Meena Ramchandani of University of Washington, Seattle, WA, USA

THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV

"COGNITIVE IMPAIRMENT IN INDIVIDUALS WITH SYPHILIS" by Kevin Robertson of University of North Carolina - Chapel Hill, Chapel Hill, NC, USA

THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV

"RESPONSE TO SYPHILIS TREATMENT: CDC GUIDELINES IN HIV-INFECTED ADULTS ON CART" by Melody Ren of University of Toronto, Toronto, Ontario, Canada

THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV

"QUESTIONS AND ANSWERS" by of

SYMPOSIUM: HIV-ASSOCIATED TUMOR VIRUSES: PARTNERS IN CRIME

"MODULATION OF HOST INNATE IMMUNITY BY KSHV" by Blossom Damania of University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

SYMPOSIUM: HIV-ASSOCIATED TUMOR VIRUSES: PARTNERS IN CRIME

"EBV: IMMUNOPATHOGENESIS AND THE PATH TO AN EBV VACCINE" by Jeffrey Cohen of NIAID, NIH, Bethesda, MD, USA

SYMPOSIUM: HIV-ASSOCIATED TUMOR VIRUSES: PARTNERS IN CRIME

"HPV: NEW INSIGHTS INTO ONCOGENESIS AND OPPORTUNITIES FOR IMMUNE CONTROL" by Denise Galloway of Fred Hutchinson Cancer Research Center, Seattle, WA, USA

SYMPOSIUM: HIV-ASSOCIATED TUMOR VIRUSES: PARTNERS IN CRIME

"HBV: FROM VIRAL INTEGRATION TO LIVER CANCER, IMPACT ON CURE STRATEGIES" by Fabien Zoulim of INSERM, Lyon, France

SYMPOSIUM: ART AND REPRODUCTION

"UPDATE ON ANTIRETROVIRAL DRUGS AND BIRTH DEFECTS" by Lynne Meryl Mofenson of Elizabeth Glaser Pediatric AIDS Foundation, Silver Spring, MD, USA

SYMPOSIUM: ART AND REPRODUCTION

"ART OPTIONS AND TREATMENT DECISIONS FOR WOMEN OF REPRODUCTIVE POTENTIAL" by Monica Gandhi of University of California San Francisco, San Francisco, CA, USA

SYMPOSIUM: ART AND REPRODUCTION

"POLICY AND PROGRAM DECISIONS FOR ART IN WOMEN OF REPRODUCTIVE POTENTIAL" by Irene Mukui of Ministry of Health, Nairobi, Kenya

SYMPOSIUM: ART AND REPRODUCTION

"CHALLENGES IN ANTIRETROVIRAL RESEARCH IN WOMEN OF REPRODUCTIVE POTENTIAL" by Anne Drapkin Lyerly of University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

SYMPOSIUM: ADDING FUEL TO THE FIRE: SUBSTANCE USE AND HIV

"CHASING THE DRAGON: OPIATES AND HIV" by Ricky N Bluthenthal of University of Southern California, Los Angeles, CA, USA

SYMPOSIUM: ADDING FUEL TO THE FIRE: SUBSTANCE USE AND HIV

"CHEMSEX AND IMPLICATIONS FOR HIV TRANSMISSION AND MANAGEMENT" by Mark Rohan Pakianathan of St George's University Hospital, London, United Kingdom

SYMPOSIUM: ADDING FUEL TO THE FIRE: SUBSTANCE USE AND HIV

"HIDDEN IN PLAIN SIGHT: THE ALCOHOL EPIDEMIC" by Leickness Chisamu Simbayi of Human Sciences Research Council, Cape Town, South Africa

SYMPOSIUM: ADDING FUEL TO THE FIRE: SUBSTANCE USE AND HIV

"TOBACCO SMOKING: THE SILENT KILLER" by Lene Ryom of CHIP, Department of Infectious Diseases, Copenhagen, Denmark

WEDNESDAY PLENARY SESSION

"RAISING THE WALL IN MATERNAL/FETAL IMMUNITY" by Sallie Permar of Duke Human Vaccine Institute, Durham, NC, USA

WEDNESDAY PLENARY SESSION

"HUGGING PHYLOGENETIC TREES: USE OF MOLECULAR ANALYSIS FOR PUBLIC HEALTH INTERVENTION" by Alexandra M. Oster of CDC, Atlanta, GA, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"ORAL ABSTRACT MODERATOR" by Stefan Sarafianos of Emory University School of Medicine, Atlanta, GA, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"A VIRUS-PACKAGEABLE CRISPR SCREEN IDENTIFIES HIV RESTRICTION AND DEPENDENCY FACTORS" by Molly Ohainle of Fred Hutchinson Cancer Research Center, Seattle, WA, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"A FUNCTIONAL MAP OF HIV-HOST INTERACTIONS IN PRIMARY HUMAN CD4+ T CELLS" by Judd F Hultquist of Northwestern University, Chicago, IL, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"HIV-1 COMPLEXES TRAFFIC WITH HOST CPSF6 ON MICROTUBULES PRIOR TO NUCLEAR ENTRY" by Zandrea Ambrose of University of Pittsburgh, Pittsburgh, PA, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"HIV-1 CAPSID DETERMINANTS THAT INFLUENCE NUCLEAR ENVELOPE DOCKING AND NUCLEAR IMPORT" by Mohamed Husen Munshi of National Cancer Institute, Frederick, MD, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"SINGLE HIV-1 VIRUS IMAGING WITH CA-EGFP QUESTIONS A ROLE OF NUCLEAR CA IN INTEGRATION" by Frauke Christ of Katholieke University Leuven, Leuven, Belgium

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"DISRUPTION OF HIV-1 LTR SEQUENCE BY A NUCLEOCAPSID MUTATION LEADS TO DTG RESISTANCE" by Atsuko Hachiya of National Hospital Organization Nagoya Medical Center, Aichi, Japan

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"INTEGRASE (IN) TETRAMERS ARE THE AUTHENTIC TARGETS FOR ALLOSTERIC HIV-1 IN INHIBITORS" by Pratibha Chowdary Koneru of University of Colorado, Aurora, CO, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"TARGETING VIRUS ENV AND CD44 IMPROVES BBAB AVIDITY AND NEUTRALIZATION POTENCY" by Djin-Ye Oh of Aaron Diamond AIDS Research Center, New York, NY, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"IPT AND PREGNANCY OUTCOMES IN HIV-POSITIVE WOMEN: THE TSHEPISO COHORT" by Nicole Salazar-Austin of Johns Hopkins University School of Medicine, Baltimore, MD, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"POTENTIAL CONCERN FOR TIMING OF DMPA INJECTION AMONG WOMEN TREATED FOR HIV AND TB" by Rosie Mngqibisa of Enhancing Care Initiative, Durban RSA, South Africa

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"IMPROVING CHILD TUBERCULOSIS CONTACT MANAGEMENT IN LESOTHO" by Yael Hirsch-Moverman of Columbia University, Mailman School of Public Health, New York, NY, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"SAFETY & PK OF WEEKLY RIFAPENTINE/ISONIAZID (3HP) IN ADULTS WITH HIV ON DOLUTEGRAVIR" by Kelly E Dooley of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"PHARMACOKINETICS AND SAFETY OF ADJUSTED DARUNAVIR/RITONAVIR WITH RIFAMPIN IN PLWH" by Gary Maartens of University of Cape Town, Cape Town, South Africa

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"EARLY BACTERICIDAL ACTIVITY OF HIGH-DOSE ISONIAZID AGAINST MULTIDRUG-RESISTANT TB" by Kelly E Dooley of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"LONG-TERM MORTALITY AFTER TUBERCULOSIS CURE IN THE CIPRA HT-001 TRIAL" by Yvetot Joseph of Les Centres GHESKIO, Haiti, Port-au-Prince, Haiti

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"QT EFFECTS OF BEDAQUILINE, DELAMANID OR BOTH IN MDR-TB PATIENTS: THE DELIBERATE TRIAL" by Gary Maartens of University of Cape Town, Cape Town, South Africa

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"FALL IN HCV INCIDENCE IN HIV+ MSM IN LONDON FOLLOWING WIDER ACCESS TO DAA THERAPY" by Lucy Jane Garvey of Imperial College Healthcare NHS Trust, London, United Kingdom

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"HCV REINFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY" by Daniel S. Fierer of Icahn School of Medicine at Mount Sinai, New York, NY, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"A PHASE 1 STUDY OF LEDIPASVIR/SOFOSBUVIR IN PREGNANT WOMEN WITH HEPATITIS C VIRUS" by Catherine Anne Chappell of Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"INCIDENT DIABETES AND GLUCOSE CONTROL AFTER HCV TREATMENT WITH DAAS IN ERCHIVES" by Adeel Ajwad Butt of Weill Cornell Medical College, New York, NY, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"INTRAHEPATIC HEPATITIS C KINETICS WITH DIRECT-ACTING ANTIVIRALS IN HIV COINFECTION" by Ashwin Balagopal of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"HIV VIREMIA AND LOW CD4+ INCREASE HCC RISK IN THOSE WITHOUT ADVANCED LIVER FIBROSIS" by Jessie Torgersen of University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"SINGLE HEPATOCYTE ANALYSIS IN HIV-HBV COINFECTION SHOWS HBV TRANSCRIPTION SILENCING" by Chloe Thio of Johns Hopkins University School of Medicine, Baltimore, MD, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"IMPACT OF UNIVERSAL TESTING AND TREATMENT IN ZAMBIA AND SOUTH AFRICA: HPTN071(POPART)" by Richard J Hayes of London School of Hygiene and Tropical Medicine, London, United Kingdom

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"A RANDOMIZED TRIAL ON INDEX HIV SELF-TESTING FOR PARTNERS OF ART CLIENTS IN MALAWI" by Kathryn Dovel of University of California Los Angeles, Westwood, CA, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"VIRAL LOAD SUPPRESSION AND YIELD OF HIV TESTS ARE SPATIALLY CORRELATED, KENYA 2015-17" by Anthony Waruru of U.S. Centers for Disease Control and Prevention, Nairobi, Kenya

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"HIV TESTING, TREATMENT, AND VIRAL SUPPRESSION COVERAGE IN A CLUSTER-RANDOMIZED TRIAL" by Kathleen Wirth of Harvard T.H. Chan School of Public Health, Boston, MA, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"FACTORS ASSOCIATED WITH PERSISTENT VIREMIA WITH UNIVERSAL “TEST & TREAT” IN UGANDA" by Eshan Uday Patel of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"VIROLOGIC FAILURE, LOW-LEVEL VIREMIA, AND VIRAL BLIP AFTER HIV RNA SUPPRESSION" by Jennifer S Lee of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"FIFTY-PERCENT REDUCTION IN HIV INCIDENCE IN CHOKWE DISTRICT, MOZAMBIQUE, 2014-2017" by Duncan Alan MacKellar of CDC, Lilburn, GA, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"A MODEL IMPACT ANALYSIS OF PREP AND TASP IN FSW DEMONSTRATION PROJECT IN BENIN" by Lily Geidelberg of Imperial College London, London, UT, United Kingdom

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"PROTECTION AGAINST PENILE OR INTRAVENOUS SHIV CHALLENGES BY BNAB 10-1074 OR 3BNC117" by David A Garber of Centers for Disease Control and Prevention, Atlanta, GA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"PROTECTION AGAINST VAGINAL SHIV INFECTION WITH AN INSERT CONTAINING TAF AND EVG" by Charles Dobard of CDC, Atlanta, GA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"MODERATE EFFICACY OF ORAL SINGLE-AGENT TAF AGAINST VAGINAL SHIV INFECTION IN MACAQUES" by Ivana Massud of Centres for Disease Control and Prevention, Atlanta, GA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"LYMPHOID TISSUE PHARMACOKINETICS OF TENOFOVIR-ALAFENAMIDE VS -DISOPROXIL FUMARATE" by Courtney V. Fletcher of University of Nebraska Medical Center, Omaha, NE, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS" by Charles B Hare of Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"USING EHR DATA TO IDENTIFY POTENTIAL PREP CANDIDATES IN A LARGE HEALTH CARE SYSTEM" by Julia L. Marcus of Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"PERSISTENCE WITH HIV PREEXPOSURE PROPHYLAXIS IN THE UNITED STATES, 2012-2016" by Ya-Lin A Huang of Centers for Disease Control and Prevention, Atlanta, GA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"IMPACT OF PREP ON DRUG RESISTANCE AND ACUTE HIV INFECTION, NEW YORK CITY, 2015-2017" by Kavita Misra of New York City Department of Health and Mental Hygiene, Long Island City, NY, USA

THEMED DISCUSSION: EARLY EVENTS

"THEMED DISCUSSION LEADER" by Michael Emerman of Fred Hutchinson Cancer Research Center, Seattle, WA, USA

THEMED DISCUSSION: EARLY EVENTS

"ENTRY KINETICS OF GLOBALLY REPRESENTATIVE AND VERTICALLY TRANSMITTED HIV ENVELOPES" by Nicholas E. Webb of University of California Los Angeles, Los Angeles, CA, USA

THEMED DISCUSSION: EARLY EVENTS

"CD4-DEPENDENT MODULATION OF HIV-1 ENTRY BY LY6E" by Shan-Lu Liu of The Ohio State University, Columbus, OH, USA

THEMED DISCUSSION: EARLY EVENTS

"ELUCIDATING MECHANISMS BY WHICH MUTATIONS IN ENV CONTRIBUTE TO HIV-1 DRUG RESISTANCE" by Rachel Van Duyne of National Cancer Institute, Frederick, MD, USA

THEMED DISCUSSION: EARLY EVENTS

"NONRANDOM GENERATION OF DELETIONS WITHIN HIV PROVIRAL SEQUENCES IN VIVO" by Bonnie Hiener of The Westmead Institute for Medical Research, Westmead, Australia

THEMED DISCUSSION: EARLY EVENTS

"HOST FACTORS INFLUENCE SIV AND HIV-1 INFECTION AND SENSITIVITY TO CAPSID INHIBITORS" by Carsten Münk of Heinrich-Heine-University Hospital, Düsseldorf, Germany

THEMED DISCUSSION: EARLY EVENTS

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS

"THEMED DISCUSSION LEADER" by John Frater of University of Oxford, Oxford, United Kingdom

THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS

"ANALYTICAL TREATMENT INTERRUPTION (ATI) IN PATIENTS WITH VERY SMALL HIV RESERVOIR" by Eric Florence of Institute of Tropical Medicine, Antwerpen, Antwerpen, Belgium

THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS

"N-803 INDUCES ROBUST SIV REACTIVATION IN ART-TREATED CD8-DEPLETED MACAQUES" by Julia Bergild McBrien of Yerkes National Primate Research Center, Atlanta, GA, USA

THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS

"REBOUND OF HIV-1 IN CEREBROSPINAL FLUID AFTER TREATMENT INTERRUPTION" by Richard W Price of University of California San Francisco, San Fransisco, CA, USA

THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS

"COMPARTMENTALIZED HIV REBOUND IN THE MALE GENITAL TRACT AFTER ART INTERRUPTION" by Sara Gianella of University of California San Diego, La Jolla, CA, USA

THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS

"SEEKING SUPPRESSION IN HAVARTI: VIREMIA & T CELLS AFTER VEDOLIZUMAB & ATI IN HIV/ART" by Michaeline McGuinty of University of Ottawa, Ottawa, Canada

THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: WEIGHT GAIN DURING ART

"THEMED DISCUSSION LEADER" by Jane A O'Halloran of Washington University in St Louis, St Louis, MO, USA

THEMED DISCUSSION: WEIGHT GAIN DURING ART

"RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR–BASED ART" by Jordan E Lake of University of Texas Health Science Center Houston, Houston, TX, USA

THEMED DISCUSSION: WEIGHT GAIN DURING ART

"GREATER WEIGHT GAIN AMONG TREATMENT-NAIVE PERSONS STARTING INTEGRASE INHIBITORS" by Kassem Bourgi of Indiana University School of Medicine, Indianapolis, IN, USA

THEMED DISCUSSION: WEIGHT GAIN DURING ART

"WEIGHT GAIN DURING TREATMENT AMONG 3,468 TREATMENT-EXPERIENCED ADULTS WITH HIV" by Grace A. McComsey of University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA

THEMED DISCUSSION: WEIGHT GAIN DURING ART

"INTEGRASE STRAND TRANSFER INHIBITORS ARE ASSOCIATED WITH WEIGHT GAIN IN WOMEN" by Anne Marie Kerchberger of Emory University, Atlanta, GA, USA

THEMED DISCUSSION: WEIGHT GAIN DURING ART

"THE IMPACT OF WEIGHT GAIN AND SEX ON IMMUNE ACTIVATION FOLLOWING INITIATION OF ART" by Sara H Bares of University of Nebraska Medical Center, Omaha, NE, USA

THEMED DISCUSSION: WEIGHT GAIN DURING ART

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: THE STATE OF THE MIND: GROWING UP WITH HIV

"THEMED DISCUSSION LEADER" by Robert Paul of University of Missouri, St. Louis, St. Louis, MO, USA

THEMED DISCUSSION: THE STATE OF THE MIND: GROWING UP WITH HIV

"YOUTH PSYCHIATRIC TRAJECTORIES PREDICT PERINATALLY HIV INFECTED YOUNG-ADULT VIREMIA" by Nadia Nguyen of New York State Psychiatric Institute, New York, NY, USA

THEMED DISCUSSION: THE STATE OF THE MIND: GROWING UP WITH HIV

"TRAJECTORY ANALYSIS OF COGNITIVE OUTCOMES IN CHILDREN WITH PERINATAL HIV" by Payal Patel of Yale University School of Medicine, New Haven, CT, USA

THEMED DISCUSSION: THE STATE OF THE MIND: GROWING UP WITH HIV

"FOCUSED COGNITIVE FUNCTION TESTING IN YOUNG PEOPLE WITH PERINATAL HIV IN ENGLAND" by Alejandro Arenas-Pinto of University College London, London, United Kingdom

THEMED DISCUSSION: THE STATE OF THE MIND: GROWING UP WITH HIV

"SYSTEMIC INFLAMMATION AND STRUCTURAL BRAIN CHANGES IN PERINATALLY HIV+ ADOLESCENTS" by Jackie Hoare of UCT, Cape Town, South Africa

THEMED DISCUSSION: THE STATE OF THE MIND: GROWING UP WITH HIV

"GENOMICS LINKS AUTOPHAGY WITH NEUROCOGNITIVE IMPAIRMENT IN HIV-INFECTED CHILDREN" by Stephen A Spector of University of California, San Diego, La Jolla, CA, USA

THEMED DISCUSSION: THE STATE OF THE MIND: GROWING UP WITH HIV

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS

"THEMED DISCUSSION LEADER" by Frank Tanser of Africa Health Research Institute, Durban, South Africa

THEMED DISCUSSION: NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS

"INCIDENT INFECTION IN HIGH-PRIORITY HIV MOLECULAR TRANSMISSION CLUSTERS" by Joel O. Wertheim of University of California, San Diego, San Diego, CA, USA

THEMED DISCUSSION: NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS

"MOLECULAR SURVEILLANCE AS A MEANS TO EXPAND AN OUTBREAK INVESTIGATION: MA, 2015-2018" by Betsey John of Massachusetts Department of Public Health, Boston, MA, USA

THEMED DISCUSSION: NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS

"HIV MOLECULAR SURVEILLANCE AND PRETREATMENT DRUG RESISTANCE IN MEXICO CITY" by Santiago Avila-Rios of National Institute of Respiratory Diseases, Mexico City, Mexico

THEMED DISCUSSION: NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS

"CLUSTER SURVEILLANCE OF FRENCH PRIMARY INFECTIONS: TOWARD A MORE VIRULENT CRF02_AG?" by Benoit Visseaux of IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité; INSERM; AP-HP, Hôpital Bichat, Virologie, Paris, France

THEMED DISCUSSION: NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS

"LITTLE OR NO OVERLAP OF SEXUAL NETWORKS OF TRANSGENDER WOMEN AND MSM IN LIMA, PERU" by Jessica Ellen Long of University of Washington, Seattle, WA, USA

THEMED DISCUSSION: NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: PLACES AND PEOPLE: MODELLING THE COSTS AND EFFECT OF INTERVENTIONS ON HIV INCIDENCE

"THEMED DISCUSSION LEADER" by Ruanne V Barnabas of University of Washington, Seattle, WA, USA

THEMED DISCUSSION: PLACES AND PEOPLE: MODELLING THE COSTS AND EFFECT OF INTERVENTIONS ON HIV INCIDENCE

"SCALE-UP OF ART AND VMMC EXPLAIN A TWO-FOLD DECLINE IN HIV INCIDENCE IN WESTERN KENYA" by Adam Akullian of Institute for Disease Modeling, Bellevue, WA, USA

THEMED DISCUSSION: PLACES AND PEOPLE: MODELLING THE COSTS AND EFFECT OF INTERVENTIONS ON HIV INCIDENCE

"EPIDEMIC IMPACT OF SUSTAINED VIREMIA AMONG FEMALE SEX WORKERS IN SOUTHERN AFRICA" by Sharmistha Mishra of University of Toronto, Toronto, Canada

THEMED DISCUSSION: PLACES AND PEOPLE: MODELLING THE COSTS AND EFFECT OF INTERVENTIONS ON HIV INCIDENCE

"ESTIMATING HIV INCIDENCE AMONG YOUNG WOMEN IN HPTN 082 USING BASELINE HIV RISK SCORES" by James Richard Moore of Fred Hutchinson Cancer Research Center, Seattle, WA, USA

THEMED DISCUSSION: PLACES AND PEOPLE: MODELLING THE COSTS AND EFFECT OF INTERVENTIONS ON HIV INCIDENCE

"COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS AMONG ADOLESCENT SEXUAL MINORITY MALES" by Li Yan Wang of Centers for Disease Control and Prevention, Atlanta, Georgia

THEMED DISCUSSION: PLACES AND PEOPLE: MODELLING THE COSTS AND EFFECT OF INTERVENTIONS ON HIV INCIDENCE

"QUESTIONS AND ANSWERS" by of

SYMPOSIUM: EXPRESS YOURSELF: PROVIRUS

"THE CURRENT STATUS OF LATENCY REVERSING AGENTS" by Carine M.C. Van Lint of Université Libre de Bruxelles, Gosselies, Belgium

SYMPOSIUM: EXPRESS YOURSELF: PROVIRUS

"DISCOVERY AND CHARACTERIZATION OF A VIRUS-INTRINSIC HIV LATENCY CIRCUIT" by Leor Weinberger of Gladstone Institutes | UCSF, San Francisco, CA, USA

SYMPOSIUM: EXPRESS YOURSELF: PROVIRUS

"SILENCING OF RETROVIRAL GENE EXPRESSION BY THE HUSH COMPLEX" by Stephen P Goff of Columbia University, New York, NY, USA

SYMPOSIUM: EXPRESS YOURSELF: PROVIRUS

"THE POWER OF THE HIV PROMOTER: IMPACT OF HIV-DRIVEN VIRAL AND HOST GENE EXPRESSION" by Ya-Chi Ho of Yale University School of Medicine, New Haven, CT, USA

SYMPOSIUM: COINFECTIONS: TUBERCULOSIS, HEPATITIS B AND C, AND HIV

"DYNAMICS OF ACUTE HCV IN WESTERN EUROPE" by Sanjay Bhagani of Royal Free Hospital, London, United Kingdom

SYMPOSIUM: COINFECTIONS: TUBERCULOSIS, HEPATITIS B AND C, AND HIV

"A VACCINE TO PREVENT HCV: ARE WE GETTING THERE?" by Andrea L Cox of Johns Hopkins University, Baltimore, MD, USA

SYMPOSIUM: COINFECTIONS: TUBERCULOSIS, HEPATITIS B AND C, AND HIV

"CHOICES AND DILEMMAS: PREVENTING TUBERCULOSIS IN PEOPLE WITH HIV INFECTION" by Amita Gupta of The Johns Hopkins University, Baltimore, MD, USA

SYMPOSIUM: COINFECTIONS: TUBERCULOSIS, HEPATITIS B AND C, AND HIV

"TREATING MULTIDRUG-RESISTANT TUBERCULOSIS IN THE REAL WORLD: NEW DRUGS AND REGIMENS" by Jennifer Furin of Harvard Medical School, Boston, MA, USA

SYMPOSIUM: THE STORY OF U: IMPLICATIONS OF UNDETECTABLE VIRAL LOAD ON TRANSMISSION

"THE STORY OF U=U: SCIENTIFIC UNDERPINNINGS" by Pietro L. Vernazza of Cantonal Hospital St. Gallen, St. Gallen, SG, Switzerland

SYMPOSIUM: THE STORY OF U: IMPLICATIONS OF UNDETECTABLE VIRAL LOAD ON TRANSMISSION

"CARING FOR U: CLINICAL CONUNDRUMS" by Nneka Nwokolo of Chelsea and Westminster Hospital, London, United Kingdom

SYMPOSIUM: THE STORY OF U: IMPLICATIONS OF UNDETECTABLE VIRAL LOAD ON TRANSMISSION

"ME AND U: COMMUNITY PERSPECTIVES" by Carrie Foote of IUPUI, Indianapolis, IN, USA

SYMPOSIUM: THE STORY OF U: IMPLICATIONS OF UNDETECTABLE VIRAL LOAD ON TRANSMISSION

"MORE THAN U: MAXIMIZING POPULATION-LEVEL EFFECTS OF U=U" by Andrew E Grulich of University of New South Wales, Sydney, NSW, Australia

THURSDAY PLENARY SESSION

"THE CHALLENGES OF HIV TREATMENT IN AN ERA OF POLYPHARMACY" by David Back of University of Liverpool, Liverpool, United Kingdom

THURSDAY PLENARY SESSION

"NEUROHIV: WHAT THE VIRUS TELLS US" by Ronald Swanstrom of University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"BRAIN CONNECTIVITY IN NEUROLOGICALLY ASYMPTOMATIC PEOPLE WITH HIV SWITCHING ART" by Jaime H Vera of Brighton and Sussex Medical School, University of Sussex, Brighton, East Sussex, United Kingdom

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"DEEP-LEARNING CEREBRAL BLOOD FLOW FOR COGNITIVE-IMPAIRMENT CLASSIFICATION IN HIV" by Patrick Luckett of Washington University in St Louis, St Louis, MO, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"HOST GLYCOMIC DETERMINANTS OF HIV-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT DURING THERAPY" by Leila Bertoni Giron of The Wistar Institute, Philadelphia, PA, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"CSF SCD30 ELEVATION DESPITE SUPPRESSIVE ART SUGGESTS CNS HIV PERSISTENCE" by Michael Peluso of University of California - San Francisco, San Francisco, CA, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"CSF HIV RNA DETECTED AT <20 COPIES/ML ASSOCIATES WITH BLOOD-BRAIN BARRIER MEASURES" by Shelli Farhadian of Yale School of Medicine, New Haven, CT, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"EFFECT ON PLASMA NFL, A MARKER OF NEURONAL INJURY, AFTER SWITCHING FROM TDF TO TAF" by Linn Hermansson of Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"CARDIOVASCULAR RISK SCORES PREDICT LONGITUDINAL COGNITIVE FUNCTION IN OLDER PLHIV" by Felicia C Chow of UCSF, San Francisco, CA, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"OBESITY IS INDEPENDENTLY ASSOCIATED WITH NEUROCOGNITIVE DECLINE IN HIV" by Kristine M Erlandson of University of Colorado, Aurora, CO, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"HIGH HIV VIRAL BURDEN PERSISTS IN CXCR3+ GCTFH DESPITE VERY EARLY ART INITIATION" by Zaza Ndhlovu of Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"SIROLIMUS REDUCES T-CELL CYCLING AND IMMUNE CHECKPOINT MARKER EXPRESSION, ACTG A5337" by Timothy J Henrich of UCSF, San Francisco, CA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"PD-1 AND CTLA-4 BLOCKADE IN MACAQUES INDUCES T-CELL EXPANSION AND SIV REACTIVATION" by Mirko Paiardini of Emory University School of Medicine, Atlanta, GA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"FTY720 LIMITS T FOLLICULAR HELPER CELL INFECTION IN LYMPHOID SITES OF SIV PERSISTENCE" by Maria Pino of Yerkes National Primate Research Center, Atlanta, GA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"TRANSCRIPTIONAL SIGNATURE OF LYMPH NODE CD8+ T CELLS IN HIV ELITE CONTROLLERS" by Son Nguyen of University of Pennsylvania, Philadelphia, PA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"CHARACTERIZING THE PROVIRAL LANDSCAPE IN HIV-1 ELITE CONTROLLERS" by Chenyang Jiang of Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"INTERFERON Α2B REDUCES INDUCIBLE CD4-ASSOCIATED HIV IN ART-SUPPRESSED INDIVIDUALS" by Livio Azzoni of The Wistar Institute, Philadelphia, PA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"NEF-STOP REPAIR DYNAMICS, BUT NOT ANTI-Α4Β7, INFLUENCE POSTTREATMENT VIRAL CONTROL" by Michele Di Mascio of NIAID, Rockville, MD, USA

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"SEARCH INTERVENTION REDUCES MORTALITY AT A POPULATION LEVEL IN MEN WITH LOW CD4 COUNT" by Moses R. Kamya of Makerere University College of Health Sciences, Kampala, Uganda

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS" by Susan Swindells of University of Nebraska Medical Center, Omaha, NE, USA

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS" by Chloe Orkin of Barts Health NHS Trust, London, United Kingdom

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR" by Jennifer E Sager of Gilead Sciences, Foster City, CA, USA

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"A PHASE IIA STUDY OF NOVEL MATURATION INHIBITOR GSK2838232 IN HIV PATIENTS" by Edwin DeJesus of Orlando Immunology Center, Orlando, FL, USA

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"SYSTEMATIC DETERMINATION OF IN VITRO HIV-1 INTEGRASE RESISTANCE FROM CLINICAL SAMPLES" by Aniqa Shahid of British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"DTG VS LPV/R (DAWNING): EFFICACY BY BASELINE NRTI RESISTANCE AND SECOND-LINE NRTI USE" by Dannae Brown of ViiV Healthcare, Surry Hills, NSW, Australia

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS" by Kathryn E. Stephenson of Beth Israel Deaconess Medical Center, Boston, MA, USA

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"MORTALITY REDUCTION IN WESTERN KENYA DURING SCALE-UP OF HIV TREATMENT, 2011-2016" by Emily C. Zielinski-Gutierrez of US Centers for Disease Control and Prevention, Nairobi, Kenya

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"OPIOID OVERDOSE DEATHS AMONG PERSONS WITH HIV INFECTION, UNITED STATES, 2011-2015" by Karin A. Bosh of Centers for Disease Control and Prevention, Atlanta, GA, USA

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"EARLY MORTALITY IN HIV-INFECTED PATIENTS INITIATING ART WITHOUT A PRETHERAPY CD4" by Kombatende Sikombe of Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"UTILITY OF CD4 CELL COUNT MONITORING IN BOTSWANA: ANALYSIS OF ROUTINE LABORATORY DATA" by Tshepo Botho Leeme of Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"TRENDS IN CD4 AND VIRAL LOAD TESTING IN SOUTHERN AFRICA: ANALYSIS OF 6 COUNTRIES" by Matthias Egger of University of Bern / Switzerland, Bern, Switzerland

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"HIGH LEVELS OF DRUG RESISTANCE AMONG ART-EXPERIENCED HOSPITALIZED PATIENTS" by Claire Bossard of Médecins Sans Frontières, Cape Town, South Africa

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"HIV DRUG RESISTANCE IN SOUTH AFRICA: RESULTS FROM A POPULATION-BASED HOUSEHOLD SURVEY" by Sizulu Moyo of Human Sciences Research Council, Cape Town, South Africa

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"DURATION OF INFECTIOUSNESS AMONG PERSONS WITH HIV DIAGNOSED DURING 2012-2016" by Nicole Crepaz of Centers for Disease Control and Prevention, Atlanta, GA, USA

THEMED DISCUSSION: ART: InSTIs AND TOXICITY

"THEMED DISCUSSION LEADER" by Alan Winston of Imperial College London, London, United Kingdom

THEMED DISCUSSION: ART: InSTIs AND TOXICITY

"NEUROPSYCHIATRIC OUTCOMES BEFORE AND AFTER SWITCHING TO DOLUTEGRAVIR-BASED THERAPY" by Phillip Chan of SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

THEMED DISCUSSION: ART: InSTIs AND TOXICITY

"NEUROPSYCHOLOGICAL CHANGES IN EFAVIRENZ SWITCH REGIMENS IN MACS" by Yijia Li of University of Pittsburgh, Pittsburgh, PA, USA

THEMED DISCUSSION: ART: InSTIs AND TOXICITY

"MEMORY AND LEARNING DYSFUNCTION WITH INTEGRASE STRAND TRANSFER INHIBITORS USE" by Jane A O'Halloran of Washington University in St Louis, St Louis, MO, USA

THEMED DISCUSSION: ART: InSTIs AND TOXICITY

"CEREBRAL FUNCTION PARAMETERS IN PEOPLE LIVING WITH HIV SWITCHING INTEGRASE INHIBITOR" by Borja Mora-Peris of Imperial College London, London, United Kingdom

THEMED DISCUSSION: ART: InSTIs AND TOXICITY

"CENTRAL NERVOUS SYSTEM EFFECTS OF THERAPY INITIATION WITH INTEGRASE INHIBITORS" by Jose A. Muñoz-Moreno of Lluita contra la SIDA Foundation - Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain

THEMED DISCUSSION: ART: InSTIs AND TOXICITY

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: HBV: RACING HIV FOR THE CURE

"THEMED DISCUSSION LEADER" by Debika Bhattacharya of University of California Los Angeles, Los Angeles, CA, USA

THEMED DISCUSSION: HBV: RACING HIV FOR THE CURE

"HEPATITIS B CURE IN HIV PATIENTS IS MORE LIKELY IN HISPANICS AND THOSE WITH AIDS" by Mamta K Jain of University of Texas Southwestern Medical Center, Dallas, TX, USA

THEMED DISCUSSION: HBV: RACING HIV FOR THE CURE

"HIGH RATES OF HBV FUNCTIONAL CURE AMONG HIV/HBV-COINFECTED PATIENTS ON ART IN ZAMBIA" by Belinda Varaidzo Chihota of Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia

THEMED DISCUSSION: HBV: RACING HIV FOR THE CURE

"HEPATITIS B VIROLOGIC FAILURE OF TENOFOVIR-BASED THERAPIES IN PATIENTS WITH HIV/HBV" by Meredith Mock of Duke University, Durham, NC, USA

THEMED DISCUSSION: HBV: RACING HIV FOR THE CURE

"HIV LATE PRESENTATION AND ITS IMPACT ON HBV SEROCONVERSION IN HBV/HIV" by Christoph Boesecke of University Hospital Bonn, Bonn, Germany

THEMED DISCUSSION: HBV: RACING HIV FOR THE CURE

"ABSENCE OF HBV REACTIVATION IN HIV/HCV/HBCAB COINFECTED PATIENTS TREATED WITH DAA" by Maddalena Cerrone of Chelsea and Westminster Hospital NHS Trust, London, UK, London, United Kingdom

THEMED DISCUSSION: HBV: RACING HIV FOR THE CURE

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: PrEP IN FITS AND STARTS

"THEMED DISCUSSION LEADER" by James A. McIntyre of Anova Health Institute, Johannesburg, South Africa

THEMED DISCUSSION: PrEP IN FITS AND STARTS

"CHANGES IN KIDNEY FUNCTION AMONG MSM INITIATING ON-DEMAND TDF/FTC FOR HIV PREP" by Geoffroy Liegeon of AP-HP, Hopital Saint Louis, Paris, France

THEMED DISCUSSION: PrEP IN FITS AND STARTS

"POINT-OF-CARE CREATININE TESTING WITHIN A PROGRAMMATIC PREP DELIVERY SETTING" by Jillian Pintye of University of Washington, Seattle, WA, USA

THEMED DISCUSSION: PrEP IN FITS AND STARTS

"IMMEDIATE PREP INITIATION AT NEW YORK CITY SEXUAL HEALTH CLINICS" by Tarek Mikati of New York City Department of Health and Mental Hygiene, Queens, NY, USA

THEMED DISCUSSION: PrEP IN FITS AND STARTS

"PREP PERSISTENCE AND DISCONTINUATIONS IN A COHORT OF YOUNG BLACK MSM IN ATLANTA, GA" by David Phillip Serota of Emory University, Atlanta, GA, USA

THEMED DISCUSSION: PrEP IN FITS AND STARTS

"LOW UPTAKE OF PREEXPOSURE PROPHYLAXIS AMONG KENYAN ADOLESCENT GIRLS AT RISK OF HIV" by Lynda Myra Oluoch of Kenya Medical Research Institute(KEMRI), NAIROBI, Kenya

THEMED DISCUSSION: PrEP IN FITS AND STARTS

"QUESTIONS AND ANSWERS" by of

THEMED DISCUSSION: TREAT ALL: TREAT FAST

"THEMED DISCUSSION LEADER" by Mohammed Limbada of Zambia AIDS Related TB Project (Zambart), Lusaka, Lusaka, Zambia

THEMED DISCUSSION: TREAT ALL: TREAT FAST

"OUTCOMES OF 'TEST AND START” AT SCALE WITHIN HAITI’S NATIONAL ART PROGRAM" by Nancy Puttkammer of University of Washington, Seattle, WA, USA

THEMED DISCUSSION: TREAT ALL: TREAT FAST

"SAME-DAY ART INITIATION IN THE SLATE TRIAL IN KENYA: PRELIMINARY RESULTS" by Sydney Rosen of Boston University, Boston, MA, USA

THEMED DISCUSSION: TREAT ALL: TREAT FAST

"IMPLEMENTING UTT IN AFRICAN CORRECTIONAL FACILITIES: A PROSPECTIVE COHORT STUDY" by Michael Herce of Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

THEMED DISCUSSION: TREAT ALL: TREAT FAST

"PATIENT-REPORTED REASONS FOR DECLINING IMMEDIATE ART INITIATION IN LUSAKA, ZAMBIA" by Jake Pry of Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

THEMED DISCUSSION: TREAT ALL: TREAT FAST

"UPTAKE OF ANTIRETROVIRAL THERAPY IN THE “TREAT ALL” ERA IN RIO DE JANEIRO, BRAZIL" by Lelia Harding Chaisson of Johns Hopkins University, Baltimore, MD, USA

THEMED DISCUSSION: TREAT ALL: TREAT FAST

"QUESTIONS AND ANSWERS" by of

SYMPOSIUM: NEW CELLS ON THE BLOCK

"TISSUE-RESIDENT MEMORY CD8+ CELLS" by Michael R Betts of University of Pennsylvania, Philadelphia, PA, USA

SYMPOSIUM: NEW CELLS ON THE BLOCK

"MECHANISMS UNDERLYING LOSS OF ILCS IN HIV/SIV-INFECTED INDIVIDUALS" by Jason Brenchley of NIAID, NIH, Bethesda,MD, USA

SYMPOSIUM: NEW CELLS ON THE BLOCK

"MEMORY NK CELLS AS NOVEL EFFECTORS AGAINST HIV AND SIV" by R. Keith Reeves of Harvard Medical School/Beth Israel Deaconess Medical Center, Boston, MA, USA

SYMPOSIUM: NEW CELLS ON THE BLOCK

"HIV SUPPRESSION BY CD8+ LYMPHOCYTES" by Deanna Kulpa of Emory University, Atlanta, GA, USA

SYMPOSIUM: TOUGH QUESTIONS IN ANTIRETROVIRAL THERAPY MANAGEMENT

"OBESITY: A GROWING PROBLEM IN ANTIRETROVIRAL THERAPY" by John R. Koethe of Vanderbilt University Medical Center, Nashville, TN, USA

SYMPOSIUM: TOUGH QUESTIONS IN ANTIRETROVIRAL THERAPY MANAGEMENT

"I KEEP FORGETTING: HIV, AGING, AND COGNITIVE DISORDERS" by Victor Valcour of University of California, San Francisco, San Francisco, CA, USA

SYMPOSIUM: TOUGH QUESTIONS IN ANTIRETROVIRAL THERAPY MANAGEMENT

"PREP FAILURES: DIAGNOSIS, RESISTANCE, AND TREATMENT" by Jean-Michel Molina of Hôpital Saint-Louis, Paris, France

SYMPOSIUM: TOUGH QUESTIONS IN ANTIRETROVIRAL THERAPY MANAGEMENT

"CAN TWO DRUGS TANGO: THE ROLE OF DUAL THERAPY" by Laura Waters of Mortimer Market Center, London, United Kingdom

SYMPOSIUM: TOUGH QUESTIONS IN ANTIRETROVIRAL THERAPY MANAGEMENT

"TRIBUTE TO DR ANREA DE LUCA" by Andrea Antinori of Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy "TRIBUTE TO DR ANREA DE LUCA" by Maurizio Zazzi of University of Siena, Siena, Italy

SYMPOSIUM: GIRLS AND BOYS JUST WANT TO HAVE FUN: MAKING PREVENTION DESIRABLE FOR YOUTH

"YOUNG TRANSGENDER INDIVIDUALS" by Asa Radix of Callen-Lorde Community Health Center, New York, NY, USA

SYMPOSIUM: GIRLS AND BOYS JUST WANT TO HAVE FUN: MAKING PREVENTION DESIRABLE FOR YOUTH

"ENGAGING YOUNG WOMEN IN SUB-SAHARAN AFRICA" by Sinead Delany-Moretlwe of Wits Reproductive Health and HIV Institute, Johannesburg, South Africa

SYMPOSIUM: GIRLS AND BOYS JUST WANT TO HAVE FUN: MAKING PREVENTION DESIRABLE FOR YOUTH

"MAKING PREVENTION WORK FOR YMSM: BRIDGING REAL-WORLD NEEDS THROUGH DIGITAL ENGAGEMENT" by Lisa Hightow-Weidman of University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

SYMPOSIUM: GIRLS AND BOYS JUST WANT TO HAVE FUN: MAKING PREVENTION DESIRABLE FOR YOUTH

"DON'T LEAVE THEM BEHIND: HETEROSEXUAL YOUNG AFRICAN MEN" by Webster Mavhu of Centre for Sexual Health & HIV/AIDS Research, Harare, Zimbabwe

SYMPOSIUM: GIRLS AND BOYS JUST WANT TO HAVE FUN: MAKING PREVENTION DESIRABLE FOR YOUTH

"QUESTIONS AND ANSWERS" by of